Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?

Passaro A Peters S Mok TSK , et al. Testing for COVID-19 in lung cancer patients. Ann Oncol. Epub ahead of print 13 April 2020. DOI: 10.1016/j.annonc.2020.04.002.

Becker PS Griffiths EA Alwan L , et al. NCCN guidelines: hematopoietic growth factors. Version 2. 2020. ▪▪▪: ▪▪▪.

Thompson CA Scheneider BJ Brahmer J , et al. NCCN guidelines: management of immunotherapy-related toxicities. Version 1. 2020.

Liang W Guan W Chen R , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335–337.

Howlader NNA Krapcho M Miller D , et al. (eds). SEER cancer statistics review, 1975–2017. Bethesda, MD: National Cancer Institute, 2020.

Drug interactions checker, https://www.drugs.com/drug_interactions.html (2020, accessed 21 April 2020).

Lexicomp® drug interactions, www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist (2020, accessed 21 April 2020).

McDonnell AM Dang CH. Basic review of the cytochrome p450 system. J Adv Pract Oncol 2013; 4: 263–268.

Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci. Epub ahead of print 14 May 2020. DOI: 10.1111/cts.12815.

Zhao Y Harmatz JS Epstein CR , et al. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol 2015; 80: 1076–1085.

Obach RS Huynh P Allen MC , et al. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 2004; 44: 7–19.

Du YX Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. Epub ahead of print 5 April 2020. DOI: 10.1002/cpt.1844.

Kochi AN Tagliari AP Forleo GB , et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020; 31: 1003–1008.

Hu LY Mi WL Wu GC , et al. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol 2019; 17: 184–196.

Short-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic. Contributions from: Abramson Cancer Center at the University of Pennsylvania; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Moffitt Cancer Center; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; Stanford Cancer Institute; UC San Diego Moores Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; and The University of Texas MD Anderson Cancer Center).

Short-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic. Contributions from: Abramson Cancer Center at the University of Pennsylvania; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Moffitt Cancer Center; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; Stanford Cancer Institute; UC San Diego Moores Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; and The University of Texas MD Anderson Cancer Center).